UGC CARE norms ugc approved journal norms IJRTI Research Journal

Click Here

International Journal for Research Trends and Innovation
International Peer Reviewed & Refereed Journals, Open Access Journal
ISSN Approved Journal No: 2456-3315 | Impact factor: 8.14 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.14 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)

Call For Paper

For Authors

Forms / Download

Published Issue Details

Editorial Board

Other IMP Links

Facts & Figure

Impact Factor : 8.14

Issue per Year : 12

Volume Published : 8

Issue Published : 85

Article Submitted : 7835

Article Published : 4002

Total Authors : 10443

Total Reviewer : 547

Total Countries : 81

Indexing Partner


This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Published Paper Details
Download E-Certificate: Download
Author Reg. ID:
Published Paper Id: IJRTI2210050
Published In: Volume 7 Issue 10, October-2022
Abstract: Objective To evaluate the efficacy and safety of dienogest treatment in patients who had received dienogest for 6 months or more to treat endometriosis with also side effects. Methods We evaluate the clinical data of 50 women of reproductive age group with endometriosis who had been treated with 2 mg of dienogest once a day for 6 months, at a single institute. We evaluated changes in endometriosis-associated pain and endometrioma size, and adverse events following dienogest administration, VAS scoring also done. Results Pain was significantly reduced at 6 months after dienogest medication. The most common adverse drug reaction was headache [42%] followed by 28% nausea and vomiting, associated with high discontinuation rates. A good satisfaction score found, so dienogest might be an effective therapeutic option for the long-term management of Endometriosis. Conclusion Finally, our study concluded that, Dienogest seems to be effective for the treatment of pain and bleeding abnormalities, associated with endometriosis. Dianogest is a safe, effective. Mean VAS significantly reduced after dianogest use.
Keywords: DNG-Dienogest GnRH-Gonadotropin-releasing hormone VAS-Visual Analog Score
Cite Article: "DRAMATIC ROLE OF DIANOGEST TO REDUCING PAIN IN ENDOMETRIOSIS ", International Journal of Science & Engineering Development Research (, ISSN:2455-2631, Vol.7, Issue 10, page no.373 - 387, October-2022, Available :
Downloads: 000202425
ISSN: 2456-3315 | IMPACT FACTOR: 8.14 Calculated By Google Scholar| ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.14 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publication Details: Published Paper ID: IJRTI2210050
Registration ID:184300
Published In: Volume 7 Issue 10, October-2022
DOI (Digital Object Identifier):
Page No: 373 - 387
Country: SATNA, Madhya Pradesh, India
Research Area: Medical Science
Publisher : IJ Publication
Published Paper URL :
Published Paper PDF:
Share Article:

Click Here to Download This Article

Article Preview
Click Here to Download This Article

Major Indexing from
Google Scholar ResearcherID Thomson Reuters Mendeley : reference manager : cornell university library Research Gate CiteSeerX DOAJ : Directory of Open Access Journals
DRJI Index Copernicus International Scribd DocStoc

ISSN Details

ISSN: 2456-3315
Impact Factor: 8.14 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016

DOI (A digital object identifier)

Providing A digital object identifier by DOI.ONE
How to Get DOI?


Open Access License Policy

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Creative Commons License This material is Open Knowledge This material is Open Data This material is Open Content

Important Details

Social Media

Join RMS/Earn 300


Indexing Partner